These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25170544)

  • 1. Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma.
    Cassarino DS; Lewine N; Cole D; Wade B; Gustavsen G
    J Med Econ; 2014 Nov; 17(11):782-91. PubMed ID: 25170544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.
    Aubry W; Lieberthal R; Willis A; Bagley G; Willis SM; Layton A
    Am Health Drug Benefits; 2013 Jan; 6(1):15-24. PubMed ID: 24991343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions.
    Hornberger J; Siegel DM
    JAMA Dermatol; 2018 Sep; 154(9):1025-1031. PubMed ID: 29998292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
    Gerami P; Alsobrook JP; Palmer TJ; Robin HS
    J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The consequences of paying Medicare managed care plans their costs.
    Sing M; Brown R; Hill SC
    Inquiry; 1998; 35(2):210-22. PubMed ID: 9719788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investment in new technology research can save future health care dollars.
    Reintgen D; Albertini J; Milliotes G; Marshburn J; Cruse CW; Rapaport D; Berman C; Glass F; Fensske N; Einstein AB; Lyman G
    J Fla Med Assoc; 1997 Mar; 84(3):175-81. PubMed ID: 9143169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease.
    Phelps CE; O'Sullivan AK; Ladapo JA; Weinstein MC; Leahy K; Douglas PS
    Am Heart J; 2014 May; 167(5):697-706.e2. PubMed ID: 24766980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic.
    Risser J; Pressley Z; Veledar E; Washington C; Chen SC
    J Am Acad Dermatol; 2007 Sep; 57(3):428-34. PubMed ID: 17624623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a prior authorization for pregabalin on health plan drug expenditures.
    Bazalo G; Weiss RC; Joshi AV
    Am J Manag Care; 2010 May; 16(5 Suppl):S154-9. PubMed ID: 20586524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.